share_log

M.D.C. Holdings Analyst Ratings

Benzinga ·  Jul 14, 2023 05:46
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
07/14/2023 16.11% Raymond James → $55 Upgrades Market Perform → Outperform
06/14/2023 Seaport Global Initiates Coverage On → Neutral
05/03/2023 -40.89% Wedbush → $28 Reiterates → Neutral
03/06/2023 -41.95% JP Morgan $30.5 → $27.5 Maintains Underweight
11/22/2022 -40.89% JP Morgan $27 → $28 Downgrades Neutral → Underweight
11/03/2022 -43% JP Morgan $31.5 → $27 Maintains Neutral
10/21/2022 Raymond James Downgrades Strong Buy → Market Perform
08/01/2022 -7.11% Raymond James $77 → $44 Maintains Strong Buy
07/12/2022 -19.78% JP Morgan $40.5 → $38 Maintains Neutral
06/17/2022 -43% Wells Fargo → $27 Downgrades Equal-Weight → Underweight
04/13/2022 -17.67% JP Morgan $49 → $39 Maintains Neutral
03/10/2022 3.44% JP Morgan $66 → $49 Maintains Neutral
11/08/2021 62.55% Raymond James $79 → $77 Maintains Strong Buy
10/14/2021 39.33% JP Morgan → $66 Downgrades Overweight → Neutral
08/19/2021 66.77% Raymond James $80 → $79 Maintains Strong Buy
04/16/2021 37.22% Wells Fargo → $65 Initiates Coverage On → Equal-Weight
03/16/2021 Wolfe Research Initiates Coverage On → Peer Perform
03/12/2021 33% B of A Securities → $63 Downgrades Neutral → Underperform
01/25/2021 49.88% Raymond James $61 → $71 Maintains Strong Buy
01/05/2021 B of A Securities Downgrades Buy → Neutral
10/30/2020 -2.89% Wells Fargo → $46 Upgrades Underweight → Equal-Weight
10/08/2020 41.44% JP Morgan → $67 Upgrades Neutral → Overweight
09/15/2020 20.33% B of A Securities → $57 Upgrades Neutral → Buy
07/29/2020 5.55% JP Morgan $38.5 → $50 Maintains Neutral
07/29/2020 28.77% Evercore ISI Group → $61 Upgrades In-Line → Outperform
06/05/2020 -21.89% Evercore ISI Group → $37 Downgrades Outperform → In-Line
04/09/2020 -26.11% Raymond James $52 → $35 Reiterates → Strong Buy
03/18/2020 -53.56% JP Morgan $46.5 → $22 Maintains Neutral
01/31/2020 -11.34% Wells Fargo $39 → $42 Downgrades Equal-Weight → Underweight
09/13/2019 -13.45% Wedbush $35 → $41 Maintains Neutral
09/13/2019 3.44% Raymond James $42 → $49 Upgrades Outperform → Strong Buy
08/01/2019 -26.11% Wedbush $30 → $35 Reiterates → Neutral
11/12/2018 -32.45% Wedbush $31 → $32 Maintains Neutral
11/02/2018 -34.56% Wedbush $34 → $31 Maintains Neutral
10/25/2018 -34.56% Evercore ISI Group $33 → $31 Upgrades In-Line → Outperform
09/21/2018 -32.45% JP Morgan $38 → $32 Downgrades Neutral → Underweight
08/02/2018 -28.22% Wedbush $33 → $34 Maintains Neutral
08/02/2018 B of A Securities Upgrades Underperform → Buy

What is the target price for M.D.C. Holdings (MDC)?

The latest price target for M.D.C. Holdings (NYSE: MDC) was reported by Raymond James on July 14, 2023. The analyst firm set a price target for $55.00 expecting MDC to rise to within 12 months (a possible 16.11% upside). 8 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for M.D.C. Holdings (MDC)?

The latest analyst rating for M.D.C. Holdings (NYSE: MDC) was provided by Raymond James, and M.D.C. Holdings upgraded their outperform rating.

When is the next analyst rating going to be posted or updated for M.D.C. Holdings (MDC)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of M.D.C. Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for M.D.C. Holdings was filed on July 14, 2023 so you should expect the next rating to be made available sometime around July 14, 2024.

Is the Analyst Rating M.D.C. Holdings (MDC) correct?

While ratings are subjective and will change, the latest M.D.C. Holdings (MDC) rating was a upgraded with a price target of $0.00 to $55.00. The current price M.D.C. Holdings (MDC) is trading at is $47.37, which is within the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment